TP53 and myelodysplastic syndrome: In particular, the response rate was not lower in patients who had failed previous HMA for MDS (CR rate of 10/17 and 40/54, for patients with or without previous HMA treatment, respectively, p = 0.361), in patients harboring TP53 mutations (CR rate of 10/13 and 18/24 for patients with or without TP53 mutations, respectively, p = 1.000), in patients with high-risk disease according to ELN 2017 (CR rate of 25/32 and 25/39, for patients with low/intermediate vs. high-risk disease, respectively, p = 0.291).